Premium
Effect of Thiol‐Containing Molecule Cysteamine on the Induction of Inducible Nitric Oxide Synthase in Hepatocytes
Author(s) -
Ozaki Takashi,
Kaibori Masaki,
Matsui Kosuke,
Tokuhara Katsuji,
Tanaka Hironori,
Kamiyama Yasuo,
Nishizawa Mikio,
Ito Seiji,
Okumura Tadayoshi
Publication year - 2007
Publication title -
journal of parenteral and enteral nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.935
H-Index - 98
eISSN - 1941-2444
pISSN - 0148-6071
DOI - 10.1177/0148607107031005366
Subject(s) - cysteamine , nitric oxide synthase , nitric oxide , chemistry , proinflammatory cytokine , nf κb , lipopolysaccharide , endocrinology , medicine , biochemistry , microbiology and biotechnology , biology , signal transduction , inflammation
Background: Cysteamine, which is a known antioxidant and anti‐inflammatory agent, is believed to be a key regulator of essential metabolic pathways in organisms. Cysteamine has beneficial effects in liver damaged by a variety of insults. During liver injury, inducible nitric oxide synthase (iNOS) is induced by lipopolysaccharide or proinflammatory cytokines, leading to excessive nitric oxide (NO) production. Accumulated evidence indicates that NO is an important factor associated with hepatic dysfunction. We examined whether cysteamine influences the induction of iNOS in hepatocytes. Methods: Primary cultured rat hepatocytes were treated with interleukin (IL)‐1β in the presence and absence of cysteamine. NO production, iNOS induction, and iNOS signal were analyzed. Results: IL‐1β stimulated the inhibitory protein κB (IκB)/nuclear factor κB (NFκB) pathway, resulting in the activation of NFκB (nuclear translocation and DNA binding), which was followed by the induction of iNOS and NO production. The addition of IL‐1β and cysteamine (1–4 mmol/L) markedly inhibited NO production, with a maximal effect at 4 mmol/L (80%–90% inhibition). Cysteamine also decreased the levels of iNOS protein and mRNA. Transfection experiments revealed that cysteamine decreased the transactivation activity of the iNOS promoter. An electrophoretic mobility shift assay demonstrated that cysteamine inhibited the activation of NFκB. Furthermore, cysteamine decreased the mRNA levels of the NFκB subunit p65 but increased those of the inhibitory protein IκB. Conclusions: These findings suggest that cysteamine inhibits iNOS induction at the step of NFκB activation. Further study is necessary to define the molecular basis of this effect of cysteamine on the regulation of NFκB and its pharmacologic implications.